219 related articles for article (PubMed ID: 18992256)
1. Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors.
Kelker MS; Page R; Peti W
J Mol Biol; 2009 Jan; 385(1):11-21. PubMed ID: 18992256
[TBL] [Abstract][Full Text] [Related]
2. Tautomycin's interactions with protein phosphatase 1.
Sydnes MO; Isobe M
Chem Asian J; 2010 Mar; 5(3):410-20. PubMed ID: 20013999
[TBL] [Abstract][Full Text] [Related]
3. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases.
Honkanen RE; Codispoti BA; Tse K; Boynton AL; Honkanan RE
Toxicon; 1994 Mar; 32(3):339-50. PubMed ID: 8016855
[TBL] [Abstract][Full Text] [Related]
4. Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors.
Connor JH; Kleeman T; Barik S; Honkanen RE; Shenolikar S
J Biol Chem; 1999 Aug; 274(32):22366-72. PubMed ID: 10428807
[TBL] [Abstract][Full Text] [Related]
5. The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity.
Liu W; Sheppeck JE; Colby DA; Huang HB; Nairn AC; Chamberlin AR
Bioorg Med Chem Lett; 2003 May; 13(9):1597-600. PubMed ID: 12699763
[TBL] [Abstract][Full Text] [Related]
6. A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure.
Colby DA; Liu W; Sheppeck JE; Huang HB; Nairn AC; Chamberlin AR
Bioorg Med Chem Lett; 2003 May; 13(9):1601-5. PubMed ID: 12699764
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of specific binding of okadaic acid to protein phosphatase 2A by microcystin-LR, calyculin-A and tautomycin: method of analysis of interactions of tight-binding ligands with target protein.
Takai A; Sasaki K; Nagai H; Mieskes G; Isobe M; Isono K; Yasumoto T
Biochem J; 1995 Mar; 306 ( Pt 3)(Pt 3):657-65. PubMed ID: 7702557
[TBL] [Abstract][Full Text] [Related]
8. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
McCluskey A; Sim AT; Sakoff JA
J Med Chem; 2002 Mar; 45(6):1151-75. PubMed ID: 11881984
[No Abstract] [Full Text] [Related]
9. Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Chattopadhyay D; Swingle MR; Salter EA; Wood E; D'Arcy B; Zivanov C; Abney K; Musiyenko A; Rusin SF; Kettenbach A; Yet L; Schroeder CE; Golden JE; Dunham WH; Gingras AC; Banerjee S; Forbes D; Wierzbicki A; Honkanen RE
Biochem Pharmacol; 2016 Jun; 109():14-26. PubMed ID: 27002182
[TBL] [Abstract][Full Text] [Related]
10. A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
Gupta V; Ogawa AK; Du X; Houk KN; Armstrong RW
J Med Chem; 1997 Sep; 40(20):3199-206. PubMed ID: 9379439
[TBL] [Abstract][Full Text] [Related]
11. Optically active cantharidin analogues possessing selective inhibitory activity on Ser/Thr protein phosphatase 2B (calcineurin): implications for the binding mode.
Baba Y; Hirukawa N; Sodeoka M
Bioorg Med Chem; 2005 Sep; 13(17):5164-70. PubMed ID: 15951185
[TBL] [Abstract][Full Text] [Related]
12. Effects of modification of the hydrophobic C-1-C-16 segment of tautomycin on its affinity to type-1 and type-2A protein phosphatases.
Takai A; Tsuboi K; Koyasu M; Isobe M
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):81-8. PubMed ID: 10926829
[TBL] [Abstract][Full Text] [Related]
13. Different moieties of tautomycin involved in protein phosphatase inhibition and induction of apoptosis.
Kawamura T; Matsuzawa S; Mizuno Y; Kikuchi K; Oikawa H; Oikawa M; Ubukata M; Ichihara A
Biochem Pharmacol; 1998 Apr; 55(7):995-1003. PubMed ID: 9605423
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhibitors of protein phosphatase 1 and 2A on erythroid colony formation: an investigation of the specificities of inhibitors.
Zhang W; Tamura J; Sakuraya M; Naruse T; Kubota K
J Int Med Res; 2001; 29(2):114-8. PubMed ID: 11393344
[TBL] [Abstract][Full Text] [Related]
15. Exploiting protein phosphatase inhibitors based on cantharidin analogues for cancer drug discovery.
Deng L; Dong J; Wang W
Mini Rev Med Chem; 2013 Jun; 13(8):1166-76. PubMed ID: 23373656
[TBL] [Abstract][Full Text] [Related]
16. Structural and Functional Analysis of the GADD34:PP1 eIF2α Phosphatase.
Choy MS; Yusoff P; Lee IC; Newton JC; Goh CW; Page R; Shenolikar S; Peti W
Cell Rep; 2015 Jun; 11(12):1885-91. PubMed ID: 26095357
[TBL] [Abstract][Full Text] [Related]
17. The apoptosis-inducing activity of the two protein phosphatase inhibitors, tautomycin and thyrsiferyl 23-acetate, is not due to the inhibition of protein phosphatases PP1 and PP2A (review).
Kikuchi K; Shima H; Mitsuhashi S; Suzuki M; Oikawa H
Int J Mol Med; 1999 Oct; 4(4):395-401. PubMed ID: 10493981
[TBL] [Abstract][Full Text] [Related]
18. PP1:Tautomycetin Complex Reveals a Path toward the Development of PP1-Specific Inhibitors.
Choy MS; Swingle M; D'Arcy B; Abney K; Rusin SF; Kettenbach AN; Page R; Honkanen RE; Peti W
J Am Chem Soc; 2017 Dec; 139(49):17703-17706. PubMed ID: 29156132
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine-272 is involved in the inhibition of protein phosphatase-1 by multiple toxins.
Zhang L; Zhang Z; Long F; Lee EY
Biochemistry; 1996 Feb; 35(5):1606-11. PubMed ID: 8634292
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of specific protein phosphatase inhibitors, tautomycin and tautomycetin toward structure-activity relationship study.
Oikawa H
Curr Med Chem; 2002 Nov; 9(22):2033-53. PubMed ID: 12369869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
